📣 VC round data is live. Check it out!

Genetic Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genetic Technologies and similar public comparables like Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics and more.

Genetic Technologies Overview

About Genetic Technologies

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.


Founded

1987

HQ

Australia

Employees

58

Financials (FY)

Revenue: $6M
EBITDA: ($8M)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Genetic Technologies Financials

Genetic Technologies reported last fiscal year revenue of $6M and negative EBITDA of ($8M).

In the same fiscal year, Genetic Technologies generated $3M in gross profit, ($8M) in EBITDA losses, and had net loss of ($9M).

Revenue (LTM)


Genetic Technologies P&L

In the most recent fiscal year, Genetic Technologies reported revenue of $6M and EBITDA of ($8M).

Genetic Technologies is unprofitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (149%), and net margin of (157%).

See analyst estimates for Genetic Technologies
Last FY20232024202620272028
Revenue$6M$6M$6M
Gross Profit$3M$3M$3M
Gross Margin51%50%51%
EBITDA($8M)($8M)($8M)
EBITDA Margin(149%)(138%)(149%)
EBIT Margin(159%)(144%)(159%)
Net Profit($9M)($9M)($9M)
Net Margin(157%)(145%)(157%)

Financial data powered by Morningstar, Inc.

Genetic Technologies Stock Performance

Genetic Technologies has current market cap of $4M, and enterprise value of $4M.

Market Cap Evolution


Genetic Technologies' stock price is $0.03.

Genetic Technologies has an EPS (earnings per share) of $-0.06.

See more trading valuation data for Genetic Technologies
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$4M-0.4%$-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Genetic Technologies Valuation Multiples

Genetic Technologies trades at 0.7x EV/Revenue multiple, and (0.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Genetic Technologies

EV / Revenue (LTM)


Genetic Technologies Financial Valuation Multiples

As of May 14, 2026, Genetic Technologies has market cap of $4M and EV of $4M.

Genetic Technologies has a P/E ratio of (0.5x).

Last FY20232024202620272028
EV/Revenue0.7x0.7x0.7x
EV/EBITDA(0.5x)(0.5x)(0.5x)
EV/EBIT(0.4x)(0.5x)(0.4x)
EV/Gross Profit1.4x1.3x1.4x
P/E(0.5x)(0.5x)(0.5x)
EV/FCF(0.6x)(0.6x)(0.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Genetic Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Genetic Technologies Margins & Growth Rates

In the most recent fiscal year, Genetic Technologies reported gross margin of 51%, EBITDA margin of (149%), and net margin of (157%).

See estimated margins and future growth rates for Genetic Technologies

Genetic Technologies Margins

Last FY2024202720282029
Gross Margin51%51%
EBITDA Margin(149%)(149%)
EBIT Margin(159%)(159%)
Net Margin(157%)(157%)
FCF Margin(127%)(127%)

Genetic Technologies Growth Rates

23/2426/2727/2828/29
Revenue Growth(6%)
Gross Profit Growth(5%)
EBITDA Growth1%
EBIT Growth4%
Net Profit Growth1%
FCF Growth(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Genetic Technologies Operational KPIs

Genetic Technologies' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Genetic Technologies
Last FY20232024202620272028
Revenue per Employee$0.1M
Opex per Employee$0.2M
S&M Expenses to Revenue34%33%34%
G&A Expenses to Revenue133%118%133%
R&D Expenses to Revenue10%12%10%
Opex to Revenue210%195%210%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Genetic Technologies Competitors

Genetic Technologies competitors include Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics, Reviva Pharmaceuticals, JFL Life Sciences, Newbury Pharmaceuticals, Institute of Biomedical, Abattis Bioceuticals and Gelteq.

Most Genetic Technologies public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Strategic Partners31.4x(4.0x)
Geovax Labs0.6x1.0x(0.1x)
Opthea1184.2x1184.2x(0.2x)
Akari Therapeutics0.0x
Reviva Pharmaceuticals0.5x
JFL Life Sciences0.5x5.3x
Newbury Pharmaceuticals1.0x(2.0x)
Institute of Biomedical

This data is available for Pro users. Sign up to see all Genetic Technologies competitors and their valuation data.

Start Free Trial

Genetic Technologies M&A Activity

Genetic Technologies has acquired 1 company to date.

Last acquisition by Genetic Technologies was on July 19th 2021. Genetic Technologies acquired EasyDNA for $4M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Genetic Technologies

EasyDNA
Description
EasyDNA is a London-headquartered genetic testing laboratory with operations across the United States through partnerships with medical clinics and practitioners. The company delivers direct-to-consumer DNA tests for paternity, health, ancestry, and wellness, processing samples via accredited labs in ISO 17025-certified facilities.
HQ CountryUnited States
HQ City
Pittsburgh, PA
Deal Date19 Jul 2021
Valuation$4M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Genetic Technologies acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Genetic Technologies

When was Genetic Technologies founded?Genetic Technologies was founded in 1987.
Where is Genetic Technologies headquartered?Genetic Technologies is headquartered in Australia.
How many employees does Genetic Technologies have?As of today, Genetic Technologies has over 58 employees.
Is Genetic Technologies publicly listed?Yes, Genetic Technologies is a public company listed on Stuttgart Stock Exchange.
What is the stock symbol of Genetic Technologies?Genetic Technologies trades under DU8 ticker.
When did Genetic Technologies go public?Genetic Technologies went public in 2002.
Who are competitors of Genetic Technologies?Genetic Technologies main competitors include Strategic Partners, Geovax Labs, Opthea, Akari Therapeutics, Reviva Pharmaceuticals, JFL Life Sciences, Newbury Pharmaceuticals, Institute of Biomedical, Abattis Bioceuticals, Gelteq.
What is the current market cap of Genetic Technologies?Genetic Technologies' current market cap is $4M.
What is the current revenue of Genetic Technologies?Genetic Technologies' last fiscal year revenue is $6M.
What is the current EV/Revenue multiple of Genetic Technologies?Current revenue multiple of Genetic Technologies is 0.7x.
Is Genetic Technologies profitable?No, Genetic Technologies is not profitable.
How many companies Genetic Technologies has acquired to date?As of May 2026, Genetic Technologies has acquired 1 company.
What was the largest acquisition by Genetic Technologies?$4M acquisition of EasyDNA on 19th July 2021 was the largest M&A Genetic Technologies has done to date.
What companies Genetic Technologies acquired?Genetic Technologies acquired EasyDNA.
In how many companies Genetic Technologies has invested to date?Genetic Technologies hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Genetic Technologies

Lists including Genetic Technologies

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial